We are live on ! Find out more
NI

Noked Israel Portfolio holdings

AUM $677M
1-Year Est. Return 69.37%
This Fund
S&P 500
This Quarter Est. Return
+32.73%
1 Year Est. Return
+69.37%
3 Year Est. Return
+201.74%
5 Year Est. Return
+303.34%
10 Year Est. Return
AUM
$81.6M
AUM Growth
-$14.3M
Cap. Flow
-$32.4M
Cap. Flow %
-39.71%
Top 10 Hldgs %
71.77%
Holding
105
New
34
Increased
2
Reduced
37
Closed
24

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.1M
2
SEDG icon
SolarEdge
SEDG
+$6.42M
3
VTRS icon
Viatris
VTRS
+$5.67M
4
DK icon
Delek US
DK
+$1.35M
5
RY icon
Royal Bank of Canada
RY
+$605K

Sector Composition

Rank Sector Weight
1 Technology 58.02%
2 Energy 11.29%
3 Healthcare 7.68%
4 Communication Services 6%
5 Financials 5.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UHAL icon
101
U-Haul Holding Co
UHAL
$14.4B
-11,000
Closed -$409K
UVV icon
102
Universal Corp
UVV
$1.3B
-5,000
Closed -$288K
VTRS icon
103
Viatris
VTRS
$20.8B
-200,000
Closed -$5.67M
KSU
104
DELISTED
Kansas City Southern
KSU
-3,800
Closed -$441K
RTN
105
DELISTED
Raytheon Company
RTN
-2,600
Closed -$473K

Similar funds

Noked Israel's Q2 2019 Portfolio in Review

As of Q2 2019, Noked Israel held 105 positions worth $81.6M, down 15% from $95.9M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Noked Israel withdrew a net $32.4M in Q2 2019, closing 24 positions and reducing 37 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Technology at 58% of assets, up from 39% a quarter earlier, followed by Energy and Healthcare.

Against the trend, Noked Israel opened a new position in Gamida Cell Ltd. Ordinary Shares worth $1.03M.

  • Noked Israel's largest Q2 2019 buy was Gamida Cell Ltd. Ordinary Shares: 203,748 shares worth $1.03M.
  • Noked Israel added most to Alphabet (Google) Class A in Q2 2019, an estimated $174K increase.
  • Noked Israel's biggest Q2 2019 reduction was SolarEdge, cutting an estimated $6.42M.
  • Noked Israel fully exited Teva Pharmaceuticals in Q2 2019, selling an estimated $12.1M.
  • Noked Israel's ten largest holdings make up 72% of its $81.6M portfolio in Q2 2019.
  • Noked Israel opened 34 new positions and closed 24 in Q2 2019.
  • Noked Israel's portfolio value fell 15% quarter-over-quarter to $81.6M.

Based on Noked Israel's 13F filing for Q2 2019, filed 15 Aug 2019.